Ischemic Monomelic Neuropathy: Diagnosis, Pathophysiology, and Management

There is an approximate growth of 3% to 4% of patients undergoing dialysis every year as a result of an increased pool of chronic kidney disease (CKD) from various medical problems such as diabetes, hypertension, and cardiovascular diseases. Arteriovenous (AV) fistula use increased from 27.9% to 55% between 1998 and 2007 (Figure 1).1 By December 2013, in 62.5% of prevalent dialysis patients an AV fistula was being used.2 In 1966, Brescia et al. introduced the endogenous AV fistula, a revolutionary therapeutic modality for the management of renal patients.